Combined low-dose cytarabine, melphalan and mitoxantone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome

Anticancer Research

Volumn 27, Issue 4 C, 2007, Pages 2635-2639

  Yamauchi, Takahiro ^a   Negoro, Eiju ^a   Arai, Hajime ^a   Ikegaya, Satoshi ^a   Takagi, Kazutaka ^a   Takemura, Haruyuki ^a   Inai, Kunihiro ^a   Yoshida, Akira ^a   Urasaki, Yoshimasa ^a   Iwasaki, Hiromichi ^a   Ueda, Takanori ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

AML; Cytarabine; Elderly patients; MDS; Melphalan; Mitoxantrone

Indexed keywords

CYTARABINE; MELPHALAN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CAUSE OF DEATH; CLINICAL ARTICLE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GERIATRIC CARE; HUMAN; LOW DRUG DOSE; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; REMISSION; SEPSIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKEMIA, MYELOID; MALE; MELPHALAN; MITOXANTRONE; PILOT PROJECTS;

EID: 34547794827     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Jabbour EJ, Estey E and Kantarjian HM: Adult acute myeloid leukemia. Mayo Clin Proc 81: 247-260, 2006.
2. Buchner T, Berdel WE, Wormann B, Schoch C, Haferlach T, Schnittger S, Kern W, Aul C, Lengfelder E, Schumacher A, Reichle A, Staib P, Balleisen L, Eimermacher H, Gruneisen A, Rasche H, Sauerland MC, Heinecke A, Mesters RM, Serve HL, Kienast J and Hiddemann W: Treatment of older patients with AML. Crit Rev Oncol Hematol 56: 247-259, 2005.
3. Godwin JE, and Smith SE: Acute myeloid leukemia in the older patient. Crit Rev Oncol Hematol 48: S17-26, 2003.
4. Larson RA: Myelodysplasia: when to treat and how. Best Pract Res Clin Haematol 19: 293-300, 2006.
5. Steensma DP and Bennett JM: The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc 81: 104-130, 2006.
6. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, Anderson JE and Petersdorf SH: Age and acute myeloid leukemia. Blood 107: 3481-3485, 2006.
7. Jabbour EJ, Estey E and Kantarjian HM: Adult acute myeloid leukemia. Mayo Clin Proc 81: 247-260, 2006.
8. Ferrara F: Unanswered questions in acute myeloid leukaemia. Lancet Oncol 5: 443-450, 2004.
9. Visani G, Malagola M, Piccaluga PP and Isidori A: Low dose ara-C for myelodysplastic syndromes: is it still a current therapy? Leuk Lymphoma 45: 1531-1538, 2004.
10. Kufe D, Spriggs D, Egan EM and Munroe D: Relationships among ara-CTP pools, formation of (ara-C)DNA, and cytotoxicity of human leukemic cells. Blood 64: 54-58, 1984.
11. Yamauchi T, Ueda T and Nakamura T: A new sensitive method for determination of intracellular 1-β-D-arabinofuranosylcytosine 5′-triphosphate content in human materials in vivo. Cancer Res 56: 1800-1804, 1996.
12. Yamauchi T, Kawai Y and Ueda T: 1-Beta-D-arabinofuranosylcytosine is cytotoxic in quiescent normal lymphocytes undergoing DNA excision repair. Jpn J Cancer Res 93: 1334-1341, 2002.
13. Yamauchi T, Nowak BJ, Keating MJ and Plunkett W: DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 7: 3580-3589, 2001.
14. Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H and Keating M: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23: 4070-4078, 2005.
15. Omoto E, Deguchi S, Takaba S, Kojima K, Yano T, Katayama Y, Sunami K, Takeuchi M, Kimura F, Harada M and Kimura I: Low-dose melphalan for treatment of high-risk myelodysplastic syndromes. Leukemia 10: 609-614, 1996.
16. Robak T, Szmigielska-Kaplon A, Urbanska-Rys H, Chojnowski K and Wrzesien-Kus A: Efficacy and toxicity of low-dose melphalan in myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia. Neoplasma 50: 172-175, 2003.
17. Apostolidou E, Estey E, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Tsimberidou A, Kantarjian H and Giles FJ: Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia. Leuk Res 27: 301-304, 2003.
18. Rizzieri DA, Bass AJ, Rosner GL, Gockerman JP, DeCastro CM, Petros WP, Adams DJ, Laughlin MJ, Davis P, Foster T, Jacobson R, Hurwitz H and Moore JO: Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia. J Clin Oncol 20: 614-619, 2002.
19. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R and Bloomfield CD: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21: 4642-4649, 2003.
20. Miller KB, Kim K, Morrison FS, Winter JN, Bennett JM, Neiman RS, Head DR, Cassileth PA and O'Connell MJ: The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study. Ann Hematol 65: 162-168, 1992.
21. Venditti A, Scimo MT, del Poeta G, Buccisano F, Stasi R, Mastino A, Grelli S, Favalli C, Garaci E and Papa G: Recombinant interferon alpha 2a, thymopentin and low doses of cytosine arabinoside for the treatment of myelodysplastic syndromes: a pilot study. Leuk Lymphoma 16: 335-342, 1995.
22. Fukuhara T, Miyake T, Maekawa I, Kurosawa M, Suzuki S, Noto S, Mori A, Chiba K, Toyoshima T, Hirano T, Morioka M, Tsutsumi Y, Okabe M and Kakinoki Y: Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study. Int J Hematol 71: 366-371, 2000.
23. Li JM, Shen Y, Wu DP, Liang H, Jin J, Chen FY, Song YP, Song EY, Qiu XF, Hou M, Qiu ZC and Shen ZX: Aclarubicin and low-dose cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients. Int J Hematol 82: 48-54, 2005.
24. Kantarjian H, O'brien S, Cortes J, Giles F, Faderl S, Jabbour E, Garcia-Manero G, Wierda W, Pierce S, Shan J and Estey E: Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 106: 1090-1098, 2006.
25. Hellstrom-Lindberg E, Robert KH, Gahrton G, Lindberg G, Forsblom AM, Kock Y and Ost A: A predictive model for the clinical response to low dose ara-C: a study of 102 patients with myelodysplastic syndromes or acute leukaemia. Br J Haematol 81: 503-511, 1992.